Inhibitors of akr1c3 and methods of use
AssigneesBoard of Regents of the University of Nebraska, The Trustees of the University of Pennsylvania
InventorsPaul Trippier, Krishnaiah Maddeboina, Sravan Jonnalagadda, Trevor Penning
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds having a structure of formula (A), or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Rd and n are described herein. Also provided herein are compositions comprising compounds of Formula (A) and methods of using compound of Formula (A) in treating, inhibiting, and/or preventing disease such as cancers (e.g., prostate cancer).
Claims23
A compound, or a pharmaceutically acceptable salt thereof, having a structure of formula (A):
- wherein
- R1 is selected from substituted or unsubstituted C6-C12aryl, substituted or unsubstituted C2-C6alkynyl, substituted or unsubstituted C1-C6alkyl, C2-C6alkenyl, substituted or unsubstituted C3-C6alkenyloxy, halo, substituted or unsubstituted C6-C10aryl-C1-C3alkyleneoxy, C6-C10aryloxy, and substituted or unsubstituted C5-C10heteroaryl having 1-4 ring heteroatoms selected from N, O, and S;
- wherein R1 is optionally substituted with one or more substituents selected from C6-C10aryl;
- 5-15 membered heteroaryl having 1-4 ring heteroatoms selected from N, O, and S;
- formyl, C3-C6cycloalkyl, halo, cycloheteroalkyl-alkylene, hydroxy-C1-C3alkylene, methoxymethyl, phenyoxy, cyano, C1-C6alkyl, C1-C6haloalkyl, and 5-7 membered fused cycloheteroalkyl having 1 to 3 ring heteroatoms selected from N, O, and S;
- R2 is selected from CO2Ra, CONRbRc, wherein each Ra, Rb, and Rc is independently H or C1-C6alkyl;
- each R3 and R4 is independently H or C1-C6alkyl;
- each Rd is independently H or C1-C3alkyl;
- and
- n is 1, 2, or 3.
(canceled)
-30. (canceled)
-42. (canceled)
Dependencies are inferred from the claim text.